Rubicon Research Pvt. Ltd. is an emerging pharmaceutical company, focused on developing value added products for the pharmaceutical industry as well as developing their portfolio of generic prescription and OTC products covering a broad range of therapeutic categories. The company is a preferred partner for the industry in the development of specialized oral solid, oral liquid and topical dosage forms. Rubicon has 13 approvals in the orange book, one filed NDA and more than 20 filed ANDA’s from their manufacturing facility. The Company operates out of three locations, the R&D center based in Thane, India; USFDA/MHRA compliant manufacturing facility based out of Ambernath, India and a marketing office based out of Princeton, New Jersey. In Jul 2018; Rubicon Research Pvt. Ltd. (Rubicon), has opened its new 38,000-sq.-ft. laboratory and corporate office in Thane, Maharashtra. This new facility provides the company with an independent facility, close to Mumbai allowing for continued growth and a more efficient workspace for its 200+ employees at this location. The new state-of-the-art R&D center is built to GMP standards and will complement Rubicon’s demonstrated expertise in formulation product development and analytical method development with the latest infrastructure and efficient design. The R&D center will now equip Rubicon to carry out complete: • Oral Solid Dosage form development from pre-formulation studies upto pilot scale in a single facility • Oral liquid dosage form development suite upto pilot scale • Topical dosage form development suite upto pilot scale • Sterile dosage form development including injectable and ophthalmic dosages • Dedicated containment suite for development of highly potent products including hormonal products and oncology products